Article Text

Download PDFPDF
Systematic review
Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefit

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests MC has assisted in the development of educational material and/or sat on advisory boards for Bayer, Boehringer Ingelheim, Pfizer, Leo Pharma, CSL Behring and Octapharma. He is a Career Investigator of the Heart and Stroke Foundation of Ontario and holds the Leo Pharma Chair in Thromboembolism Research at McMaster University. DG has chaired or served on advisory boards for Boehringer Ingelheim, Bristol Meyers Squibb and Daiichi Sankyo and he has contributed to the development of educational materials used by Boehringer Ingelheim